Patent foramen ovale and cryptogenic stroke: The hole story

Stroke

Volumn 44, Issue 9, 2013, Pages 2676-2678

  Furlan, Anthony J ^a   Jauss, Marek ^b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

Embolism paradoxical; Patent foramen ovale; Stroke

Indexed keywords

ARTICLE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; DIFFUSION WEIGHTED IMAGING; EMBOLISM; HEART ATRIUM SEPTUM DEFECT; HEART VENTRICLE SEPTUM DEFECT; HUMAN; INTENTION TO TREAT ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PARADOXICAL EMBOLISM; PATENT FORAMEN OVALE; PRIORITY JOURNAL; REIMBURSEMENT; TRANSIENT ISCHEMIC ATTACK;

EMBOLISM PARADOXICAL; PATENT FORAMEN OVALE; STROKE;

FORAMEN OVALE, PATENT; HUMANS; PATIENT SELECTION; PROSTHESES AND IMPLANTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE;

EID: 84884501842     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.113.001676     Document Type: Article

References (12)

1. Thaler DE, Wahl A. Critique of closure or medical therapy for cryptogenic stroke with patent foramen ovale: the hole truth? Stroke. 2012;43:3147-3149.
2. Furlan AJ. Letter by Furlan regarding "critique of closure or medical therapy for cryptogenic stroke with patent foramen ovale: the hole truth?". Stroke. 2013;44:e9.
3. Furlan AJ, Reisman M, Massaro J, Mauri L, Adams H, Albers GW, et al. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N Engl J Med. 2012;366:991-999.
4. Meier B, Kalesan B, Mattle HP, Khattab AA, Hildick-Smith D, Dudek D, et al. Percutaneous closure of patent foramen ovalein cryptogenic embolism. N Engl J Med. 2013;368:1083-1091.
5. Carroll JD, Saver JL, Thaler DE, Smalling RW, Berry, MacDonald LA, et al. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. N Engl J Med. 2013;368:1092-1100.
6. Maisel WH, Laskey WK. Patent foramen ovale closure devices: moving beyond equipoise. JAMA. 2005;294:366-369.
7. Kitsios GD, Dahabreh IJ, Abu Dabrh AM, Thaler DE, Kent DM. Patent foramen ovale closure and medical treatments for secondary stroke prevention: a systematic review of observational and randomized evidence. Stroke. 2012;43:422-431.
8. Messé SR, Kent DM. Still no closure on the question of PFO closure. N Engl J Med. 2013;368:1152-1153.
9. Homma S, Sacco RL, Di Tullio MR, Sciacca RR, Mohr JP; PFO in Cryptogenic Stroke Study (PICSS) Investigators. Effect of medical treatment in stroke patients with patent foramen ovale: patent foramen ovale in Cryptogenic Stroke Study. Circulation. 2002;105:2625-2631.
10. Messé SR, Silverman IE, Kizer JR, Homma S, Zahn C, Gronseth G, et al; Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: recurrent stroke with patent foramen ovale and atrial septal aneurysm: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2004;62:1042-1050.
11. Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, et al; for the AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364: 806-817.
12. Thaler DE, Ruthazer R, Angelantonio ED, Di Tullio MR, Donovan JS, Elkind SV, et al. Neuroimaging findings in cryptogenic stroke patients with and without PFO. Stroke. 2013;44:675-680.